Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Eisleben – page 3

361 clinical trials in Eisleben, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Eisleben at a glance
361
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

361 trials in Eisleben

Open in trial search

First-line treatment of metastatic non‑small cell lung cancer with high PD‑L1 expression: ivonescimab versus pembrolizumab

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ivonescimab
  • Sponsor:Summit Therapeutics Inc.

Long-Term Safety Study of Asciminib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bosutinib
  • Sponsor:Novartis Pharma AG

Anaemia+1

Recruiting

A Phase 3 Study of Elritercept Versus Epoetin Alfa in ESA‑Naïve Adults with Lower‑Risk Myelodysplastic Syndrome Requiring Red Blood Cell Transfusions

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Elritercept
  • Sponsor:Takeda Development Center Americas Inc.

A Study Testing Casdatifan and Cabozantinib Compared to Placebo and Cabozantinib in Patients With Advanced Clear Cell Kidney Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AB521
  • Sponsor:Arcus Biosciences Inc.

Study on the Effectiveness of Green Tea Leaf Extract Ointment for Adults with Actinic Keratosis on the Scalp and Face

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Camellia Sinensis (Green Tea) Leaf Extract
  • Sponsor:Aresus Pharma GmbH

Study of LY3537982, pembrolizumab, and a drug combination for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Eli Lilly & Co.

Phase 2 Study of Imzokitug with drug combination as First‑Line Treatment for Adults with Locally Advanced or Metastatic Non‑Small Cell Lung Cancer (NSCLC)

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BMS-986340
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study of belumosudil versus drug combination in patients aged 12 years and older with chronic graft‑versus‑host disease refractory after prior therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Belumosudil
  • Sponsor:Sanofi-Aventis Recherche & Developpement

A Phase 3 Study of Sapablursen Compared with Placebo in Adults with Polycythemia Vera

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Sapablursen
  • Sponsor:Deciphera Pharmaceuticals Inc.

Phase III Randomized Open‑Label Trial of BNT324 vs Docetaxel Plus Prednisone in Patients with Metastatic Castration‑Resistant Prostate Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BNT324
  • Sponsor:BioNTech SE

Efficacy and Safety of JNJ-78934804 (guselkumab and golimumab) in Adults with Moderately to Severely Active Ulcerative Colitis

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Golimumab
  • Sponsor:Janssen Cilag International

Durvalumab plus drug combination as total neoadjuvant therapy for patients with resectable gastroesophageal adenocarcinoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Eisleben

What the registry says about research in the country

01 Neoplasms

The clinical trial activity in Lutherstadt Eisleben is focused on cancer research, with studies exploring new treatment options for advanced disease. These trials aim to improve outcomes for patients by comparing emerging therapies with established standard care.

  • Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
  • Locally Advanced or Metastatic Urothelial Carcinoma
  • Testing new therapy combinations against current cancer treatments
  • Evaluating treatment effectiveness in difficult-to-treat tumors

Overall, the research here reflects a strong interest in improving care for advanced solid tumors, especially through better disease control and survival outcomes.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.